Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B - II | Alive

Total Raised


Last Raised

$60M | 9 mos ago

About Cure Genetics

Suzhou Cure Genetics Biotechnology, dba Cure Genetics, is a transformational biotechnology company focused on CRISPR gene-editing technology for cell therapy drug applications.

Cure Genetics Headquarters Location

Room 510, Building A4, Shengwu Nami Park Suzhou Industry Park No.218

Suzhou, Jiangsu,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cure Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cure Genetics is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Cure Genetics Patents

Cure Genetics has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics



Molecular biology, Transplantation medicine, Genetics, Biotechnology, Ribonucleases


Application Date


Grant Date


Related Topics

Molecular biology, Transplantation medicine, Genetics, Biotechnology, Ribonucleases



Latest Cure Genetics News

Cure Genetics Raises $60 Million to Advance Universal CAR-T Products

Jan 25, 2022

publication date: Jan 25, 2022 Cure Genetics of Suzhou closed a $60 million Series B round to advance clinical development of its cell therapy candidates for hematological and solid tumors. Cure was established by CRISPR pioneers in 2016 to develop therapies for difficult-to-treat cancers and genetic diseases. Its CRISPR-mediated single or multiplex gene editing platform is aimed at producing more effective or safer cell therapy products, including universal CAR-T candidates. The financing round was led by Advantech Capital and joined by Oriza Holdings, Blue Ocean Private Equity and Qiming Venture Capital. More details.... Share this with colleagues: Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .

Cure Genetics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cure Genetics Rank

  • When was Cure Genetics founded?

    Cure Genetics was founded in 2016.

  • Where is Cure Genetics's headquarters?

    Cure Genetics's headquarters is located at Room 510, Building A4, Shengwu Nami Park, Suzhou.

  • What is Cure Genetics's latest funding round?

    Cure Genetics's latest funding round is Series B - II.

  • How much did Cure Genetics raise?

    Cure Genetics raised a total of $113.66M.

  • Who are the investors of Cure Genetics?

    Investors of Cure Genetics include Qiming Venture Partners, Oriza Holdings, Advantech Capital, Blue Ocean Capital Group, Ascendin Fund and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.